Abstracts Archive - Page 788 of 2425 - ACR Meeting Abstracts

Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…
Abstract Number: 2001 • ACR Convergence 2020
Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial
Kathleen Vanni¹, Nancy Berliner¹, Nina Paynter², Robert Glynn², Jean MacFadyen¹, Joshua Colls¹, Fengxin Lu¹, Chang Xu², Paul Ridker¹ and Daniel H Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: Low dose methotrexate (LD-MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia and leukopenia, but…
Abstract Number: 2002 • ACR Convergence 2020
Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib
Kevin Winthrop¹, Peter Nash², Kunihiro Yamaoka³, Eduardo Mysler⁴, Leonard Calabrese⁵, Nasser Khan⁶, Jeffrey Enejosa⁶, Yanna Song⁷, Jessica Suboticki⁶ and Jeffrey Curtis⁸, ¹Oregon Health & Science University, Portland, OR, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁴Organización Medica de Investigación, Buenos Aires, Argentina, ⁵Cleveland Clinic, Cleveland, OH, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Upadacitinib (UPA) is an oral JAK inhibitor approved for the treatment of rheumatoid arthritis (RA). The background rate of herpes zoster (HZ) in patients…
Abstract Number: 2003 • ACR Convergence 2020
Individualized Prediction of Response to Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics-driven Machine Learning Approach
Elena Myasoedova¹, Arjun Athreya¹, Cynthia Crowson², Richard Weinshilboum¹, Liewei Wang¹ and Eric Matteson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Methotrexate (MTX) is the most common anchor drug for rheumatoid arthritis (RA), but the risk of missing the opportunity for early effective treatment with alternative medications…
Abstract Number: 2004 • ACR Convergence 2020
Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Maria Luque-Tevar¹, Carlos Pérez-Sánchez¹, Pilar Font², Alejandra Maria Patiño-Trives¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Carmen Torres-Granados¹, Montserrat Romero-Gomez², Desirée Ruiz-Vilchez², Rafaela Ortega-Castro³, Alejandro Escudero-Contreras⁴, Carlos Rodriguez-Escalera⁵, Jose Perez-Venegas⁶, Mª Dolores Ruiz-Montesinos⁶, Carmen Dominguez⁶, Carmen Romero-Barco⁷, Antonio Fernandez-Nebro⁸, Natalia Mena-Vazquez⁹, Jose Luis Marenco¹⁰, Julia Uceda-Montañez¹⁰, Mª Dolores Toledo-Coello¹¹, Nuria Barbarroja⁴, M Angeles Aguirre² and Eduardo Collantes², ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴IMIBIC/Hospital Reina Sofia /Universidad de Cordoba., Córdoba, Spain, ⁵Hospital Universitario de Jaen, Jaén, Spain, ⁶Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, ⁷Hospital Clínico Universitario, Málaga, Málaga, Spain, ⁸University of Malaga, Malaga, Spain, ⁹Hospital Regional Universitario de Málaga, Málaga, Spain, ¹⁰Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, ¹¹Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain
Background/Purpose: To evaluate changes produced in circulating inflammatory mediators and their regulatory miRNAs in RA patients after 3 and 6 months of treatment with TNF-α inhibitors…
Abstract Number: 2005 • ACR Convergence 2020
Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby², Giovanni Giorli², Alessandra Nerviani¹, Rebecca Hands², Liliane Fossati-Jimack², Georgina Thorborn², Myles Lewis¹ and Costantino Pitzalis², ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom
Background/Purpose: The results of the R4RA trial, the first biopsy-based RCT in TNF-i inadequate responders patients with Rheumatoid Arthritis (RA), showed that molecular stratification of…
Abstract Number: 2006 • ACR Convergence 2020
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Markus Rehberg¹, Clemens Giegerich¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Jeffrey R Curtis⁴, Jacques-Eric Gottenberg⁵, Andreas Schwarting⁶, Santos Castañeda⁷, Andrea Rubbert Roth⁸ and Ernest Choy⁹, ¹Sanofi, Frankfurt, Germany, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Strasbourg University Hospital, Strasbourg, France, ⁶Johannes Gutenberg University, Mainz, Germany, ⁷Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ⁸Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ⁹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…
Abstract Number: 2007 • ACR Convergence 2020
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate
Peter Taylor¹, Bryan Downie², Emon Elboudwarej², Sam Kim², Angie Hertz², Amer Mirza², Jeff Siegel³, Rachael Hawtin² and Jinfeng Liu², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA).…
Abstract Number: 2008 • ACR Convergence 2020
Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Emilie Sapart¹, Tatiana Sokolova¹, Stéphanie de Montjoye¹, Stéphanie Dierckx², Adrien Nzeusseu Toukap³, Aleksandra Avramovska¹ and Patrick Durez⁴, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: The EULAR recommendations, updated in 20161 and 20192, propose the initiation of glucocorticoid (GC) therapy in combination with cDMARDs background therapy for every patient…
Abstract Number: 2009 • ACR Convergence 2020
Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study
Linda Hartman¹, Linda Rasch², Samina Turk³, Marieke ter Wee¹, Pit Kerstens⁴, Conny van der Laken⁵, Mike Nurmohamed⁶, Dirkjan van Schaardenburg⁷, Lilian van Tuyl⁸, Alexandre Voskuyl¹, Maarten Boers⁷ and Willem Lems¹, ¹Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, ³Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands, ⁴Westfriesgasthuis, Hoorn, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ⁷Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁸Nivel, Utrecht, Netherlands
Background/Purpose: EULAR guidelines advise to start with methotrexate (MTX) for early rheumatoid arthritis (RA), either alone or combined with prednisolone. Since this strategy is not…
Abstract Number: 2010 • ACR Convergence 2020
Stable versus Tapered and Withdrawn Treatment with Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis Remission: A Randomized, Open-Label, Phase 4, Non-Inferiority Trial
Siri Lillegraven¹, Nina Paulshus Sundlisæter¹, Anna-Birgitte Aga¹, Joseph Sexton¹, Inge C. Olsen², Åse Lexberg³, Tor Magne Madland⁴, Hallvard Fremstad⁵, Christian Høili⁶, Gunnstein Bakland⁷, Cristina Spada⁸, Hilde Haukeland⁹, Inger Myrnes Hansen¹⁰, Ellen Moholt¹, Till Uhlig¹, Daniel H. Solomon¹¹, Désirée van der Heijde¹², Tore K. Kvien¹ and Espen A. Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Vestre Viken HF, Drammen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Ålesund Hospital, Ålesund, Norway, ⁶Hospital Øsftfold HF, Moss, Norway, ⁷University Hospital of North Norway, Tromsø, Norway, ⁸Revmatismesykehuset, Lillehammeer, Norway, ⁹Martina Hansens Hospital, Bærum, Norway, ¹⁰Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ¹²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Remission is the preferred treatment target in rheumatoid arthritis (RA), and many patients require biologic disease-modifying antirheumatic drugs (DMARDs) to reach this state. It…
Abstract Number: 2011 • ACR Convergence 2020
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Evgeny Nasonov¹, Saeed Fatenejad², Mariana Ivanova³, Diana Krechikova⁴, Sofia Kuzkina⁵, Alexey Maslyanskiy⁶, Tatiana Plaksina⁷, Mikhail Samsonov⁵, Marina Stanislav¹, Tamara Tyabut⁸, Irina Vinogradova⁹, Sergey Yakushin¹⁰, Elena Zonova¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, LLC, Charlotte, NC, ³UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"”, Smolensk, Russia, ⁵JSC “R-Pharm”, Moscow, Russia, ⁶SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov", Saint Petersburg, Russia, ⁷SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", Nizhny Novgorod, Russia, ⁸Belarusian Medical Academy of Postgraduate Education, Minsk, Russia, ⁹Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic, Novosibirsk, Russia, ¹²Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…
Abstract Number: 2012 • ACR Convergence 2020
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
Charles Peterfy¹, Maya Buch², Ernest Choy³, Georg Schett⁴, Dana Parsons-Rich⁵, Anand Patel⁶, Yulia Zima⁵, Claire Le Bolay⁷ and Mark Genovese⁸, ¹Spire Sciences, Inc., Boca Raton, FL, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, ⁷Merck KGaA, Darmstadt, Germany, ⁸Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in multiple signalling pathways potentially implicated in rheumatoid arthritis (RA). Evobrutinib is a highly selective, oral BTK inhibitor.…
Abstract Number: 2013 • ACR Convergence 2020
Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Familial occurrence of ankylosing spondylitis (AS) is well known. Our follow-up study aimed at assessing the incidence of clinically defined AS among first degree…
Abstract Number: 2014 • ACR Convergence 2020
The Relative Diagnostic Utility of Inflammatory Back Pain Criteria in an Inception Cohort of Patients with Psoriasis, Iritis, and Colitis Presenting with Undiagnosed Back Pain
Georg Kröber¹, Ulrich Weber², Raj Carmona³, James Yeung⁴, Jon Chan⁵, Sibel Aydin⁶, Liam Martin⁷, Ariel Masetto⁸, Stephanie Keeling⁹, Olga Ziouzina⁷, Sherry Rohekar¹⁰, Rana Dadashova¹¹, Joel Paschke¹¹, Amanda Carapellucci¹¹, Robert G Lambert¹² and Walter Maksymowych⁹, ¹University of Southern Denmark, Sønderborg, Denmark, ²University of South Denmark, Odense, Denmark, ³St. Joseph's Healthcare, Hamilton, ON, Canada, ⁴James Yeung Rheumatology, Vancouver, BC, Canada, ⁵Artus Health Clinic, Vancouver, BC, Canada, ⁶University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Lawson Health Research Institute, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, AB, Canada, ¹²University of Alberta and CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Patients with psoriasis, iritis, or colitis and back pain represent a high-risk population for the presence of axial spondyloarthritis (axSpA). Clinicians rely on the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.